State Street Corp Allogene Therapeutics, Inc. Transaction History

State Street Corp

  • $2.41 Trillion
  • Q3 2024

A detailed history of State Street Corp transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 7,013,083 shares of ALLO stock, worth $14.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,013,083
Previous 7,668,124 8.54%
Holding current value
$14.7 Million
Previous $17.9 Million 9.91%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$2.08 - $3.5 $1.36 Million - $2.29 Million
-655,041 Reduced 8.54%
7,013,083 $19.6 Million
Q2 2024

Aug 14, 2024
SELL
$2.23 - $4.38 $3.38 Million - $6.64 Million
-1,515,887 Reduced 16.51%
7,668,124 $17.9 Million
Q1 2024

May 15, 2024
BUY
$2.92 - $5.63 $19.7 Million - $38 Million
6,756,727 Added 278.37%
9,184,011 $41.1 Million
Q4 2023

Feb 14, 2024
SELL
$2.28 - $3.5 $13.2 Million - $20.2 Million
-5,775,317 Reduced 70.41%
2,427,284 $7.79 Million
Q3 2023

Nov 14, 2023
SELL
$3.17 - $5.96 $875,427 - $1.65 Million
-276,160 Reduced 3.26%
8,202,601 $26 Million
Q2 2023

Aug 14, 2023
BUY
$4.53 - $6.74 $1.21 Million - $1.8 Million
267,687 Added 3.26%
8,478,761 $42.1 Million
Q1 2023

May 15, 2023
SELL
$4.92 - $8.21 $4.7 Million - $7.84 Million
-955,334 Reduced 10.42%
8,211,074 $40.6 Million
Q4 2022

Feb 14, 2023
BUY
$5.62 - $11.11 $14 Million - $27.6 Million
2,486,111 Added 37.22%
9,166,408 $57.7 Million
Q3 2022

Nov 15, 2022
BUY
$10.32 - $17.28 $10.6 Million - $17.7 Million
1,025,973 Added 18.14%
6,680,297 $72.1 Million
Q2 2022

Aug 15, 2022
SELL
$6.78 - $12.28 $15.1 Million - $27.3 Million
-2,223,324 Reduced 28.22%
5,654,324 $64.5 Million
Q1 2022

May 16, 2022
BUY
$7.65 - $15.29 $26.5 Million - $53 Million
3,464,603 Added 78.51%
7,877,648 $71.8 Million
Q4 2021

Feb 14, 2022
BUY
$13.13 - $24.52 $11.8 Million - $22.1 Million
899,729 Added 25.61%
4,413,045 $65.8 Million
Q3 2021

Nov 15, 2021
BUY
$21.01 - $27.64 $10.7 Million - $14.1 Million
508,416 Added 16.92%
3,513,316 $90.3 Million
Q2 2021

Aug 16, 2021
BUY
$23.49 - $35.8 $15.8 Million - $24 Million
671,104 Added 28.76%
3,004,900 $78.4 Million
Q1 2021

May 17, 2021
SELL
$25.79 - $39.02 $26.8 Million - $40.6 Million
-1,039,665 Reduced 30.82%
2,333,796 $82.4 Million
Q4 2020

Feb 16, 2021
BUY
$25.24 - $43.45 $20.4 Million - $35.2 Million
809,829 Added 31.59%
3,373,461 $85.1 Million
Q3 2020

Nov 10, 2020
BUY
$32.38 - $44.96 $9.9 Million - $13.8 Million
305,841 Added 13.55%
2,563,632 $96.7 Million
Q2 2020

Aug 14, 2020
BUY
$18.39 - $54.04 $10.4 Million - $30.5 Million
563,575 Added 33.26%
2,257,791 $96.7 Million
Q1 2020

May 11, 2020
BUY
$18.22 - $28.25 $30.9 Million - $47.9 Million
1,694,216 New
1,694,216 $32.9 Million

Others Institutions Holding ALLO

# of Institutions
163
Shares Held
134M
Call Options Held
59.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $301M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email